Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 74, Issue 2 SUPPL., 2006, Pages

  Eldor, Roy ^a   Raz, Itamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Adipokines; Beta cell; Diabetes mellitus type 2; Lipotoxicity; Obesity

Indexed keywords

ADIPONECTIN; ADIPSIN; APELIN; INTERLEUKIN 6; LEPTIN; PROTEIN; RESISTIN; RETINOL BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISFATIN;

ADIPOSE TISSUE; ADIPOTOXICITY; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL SURVIVAL; FATTY ACID BLOOD LEVEL; HUMAN; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; TOXICITY;

EID: 33749244427     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.06.004     Document Type: Article

References (76)

1. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 122 (1995) 481-486
2. Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., and DeFronzo R.A. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab. 90 (2005) 493-500
3. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
4. Deng S., Vatamaniuk M., Huang X., Doliba N., Lian M.M., Frank A., et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53 (2004) 624-632
5. Paolisso G., Tataranni P.A., Foley J.E., Bogardus C., Howard B.V., and Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of niddm. Diabetologia 38 (1995) 1213-1217
6. Unger R.H., Zhou Y.T., and Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 2327-2332
7. Cnop M., Welsh N., Jonas J.C., Jorns A., Lenzen S., and Eizirik D.L. Mechanisms of pancreatic {beta}-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 Suppl. 2 (2005) S97-S107
8. Eizirik D.L., Flodstrom M., Karlsen A.E., and Welsh N. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39 (1996) 875-890
9. Yamashita T., Eto K., Okazaki Y., Yamashita S., Yamauchi T., Sekine N., et al. Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 145 (2004) 3566-3577
10. Medvedev A.V., Snedden S.K., Raimbault S., Ricquier D., and Collins S. Transcriptional regulation of the mouse uncoupling protein-2 gene. Double e-box motif is required for peroxisome proliferator-activated receptor-gamma-dependent activation. J. Biol. Chem. 276 (2001) 10817-10823
11. Chan C.B., De Leo D., Joseph J.W., McQuaid T.S., Ha X.F., Xu F., et al. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes 50 (2001) 1302-1310
12. Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N. Engl. J. Med. 345 (2001) 1772-1774
13. Zhang C.Y., Baffy G., Perret P., Krauss S., Peroni O., Grujic D., et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105 (2001) 745-755
14. Lau D.C., Dhillon B., Yan H., Szmitko P.E., and Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H2031-H2041
15. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 115 (2005) 911-919 (quiz 920)
16. Fasshauer M., and Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 46 (2003) 1594-1603
17. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., and Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in ap2, the adipocyte fatty acid binding protein. Science 274 (1996) 1377-1379
18. Park H.S., Park J.Y., and Yu R. Relationship of obesity and visceral adiposity with serum concentrations of crp, tnf-alpha and il-6. Diabetes Res. Clin. Pract. 69 (2005) 29-35
19. Pedersen M., Bruunsgaard H., Weis N., Hendel H.W., Andreassen B.U., Eldrup E., et al. Circulating levels of tnf-alpha and il-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech. Ageing Dev. 124 (2003) 495-502
20. Hotamisligil G.S., Budavari A., Murray D., and Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin. Invest. 94 (1994) 1543-1549
21. Zhang S., and Kim K.H. Tnf-alpha inhibits glucose-induced insulin secretion in a pancreatic beta-cell line (ins-1). FEBS Lett. 377 (1995) 237-239
22. Campbell I.L., Iscaro A., and Harrison L.C. Ifn-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of langerhans. J. Immunol. 141 (1988) 2325-2329
23. Sekine N., Ishikawa T., Okazaki T., Hayashi M., Wollheim C.B., and Fujita T. Synergistic activation of nf-kappab and inducible isoform of nitric oxide synthase induction by interferon-gamma and tumor necrosis factor-alpha in ins-1 cells. J. Cell. Physiol. 184 (2000) 46-57
24. Cetkovic-Cvrlje M., and Eizirik D.L. Tnf-alpha and ifn-gamma potentiate the deleterious effects of il-1 beta on mouse pancreatic islets mainly via generation of nitric oxide. Cytokine 6 (1994) 399-406
25. Ofei F., Hurel S., Newkirk J., Sopwith M., and Taylor R. Effects of an engineered human anti-tnf-alpha antibody (cdp571) on insulin sensitivity and glycemic control in patients with niddm. Diabetes 45 (1996) 881-885
26. Fried S.K., Bunkin D.A., and Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83 (1998) 847-850
27. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
28. Lagathu C., Bastard J.P., Auclair M., Maachi M., Capeau J., and Caron M. Chronic interleukin-6 (il-6) treatment increased il-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 311 (2003) 372-379
29. Testa R., Olivieri F., Bonfigli A.R., Sirolla C., Boemi M., Marchegiani F., et al. Interleukin-6-174 g > c polymorphism affects the association between il-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res. Clin. Pract. 71 (2006) 299-305
30. Campbell I.L., Cutri A., Wilson A., and Harrison L.C. Evidence for il-6 production by and effects on the pancreatic beta-cell. J. Immunol. 143 (1989) 1188-1191
31. Choi S.E., Choi K.M., Yoon I.H., Shin J.Y., Kim J.S., Park W.Y., et al. Il-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl. Immunol. 13 (2004) 43-53
32. Otero M., Lago R., Lago F., Casanueva F.F., Dieguez C., Gomez-Reino J.J., et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 579 (2005) 295-301
33. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334 (1996) 292-295
34. Elmquist J.K. Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. Physiol. Behav. 74 (2001) 703-708
35. Petersen K.F., Oral E.A., Dufour S., Befroy D., Ariyan C., Yu C., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109 (2002) 1345-1350
36. Fischer S., Hanefeld M., Haffner S.M., Fusch C., Schwanebeck U., Kohler C., et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 39 (2002) 105-110
37. Widjaja A., Stratton I.M., Horn R., Holman R.R., Turner R., and Brabant G. Ukpds 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J. Clin. Endocrinol. Metab. 82 (1997) 654-657
38. Tatti P., Masselli L., Buonanno A., Di Mauro P., and Strollo F. Leptin levels in diabetic and nondiabetic subjects. Endocrine 15 (2001) 305-308
39. Boden G., Chen X., Kolaczynski J.W., and Polansky M. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J. Clin. Invest. 100 (1997) 1107-1113
40. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 53 Suppl. 1 (2004) S152-S158
41. Maedler K., Sergeev P., Ehses J.A., Mathe Z., Bosco D., Berney T., et al. Leptin modulates beta cell expression of il-1 receptor antagonist and release of il-1beta in human islets. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 8138-8143
42. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the pima indian population. Lancet 360 (2002) 57-58
43. Putz D.M., Goldner W.S., Bar R.S., Haynes W.G., and Sivitz W.I. Adiponectin and c-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism 53 (2004) 1454-1461
44. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
45. Rakatzi I., Mueller H., Ritzeler O., Tennagels N., and Eckel J. Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line ins-1. Diabetologia 47 (2004) 249-258
46. Winzell M.S., Nogueiras R., Dieguez C., and Ahren B. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem. Biophys. Res. Commun. 321 (2004) 154-160
47. Staiger K., Stefan N., Staiger H., Brendel M.D., Brandhorst D., Bretzel R.G., et al. Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J. Clin. Endocrinol. Metab. 90 (2005) 6707-6713
48. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
49. Fain J.N., Cheema P.S., Bahouth S.W., and Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 300 (2003) 674-678
50. Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Busse R., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49 (2006) 744-747
51. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med. Sci. Monit. 9 (2003) RA55-RA61
52. Utzschneider K.M., Carr D.B., Tong J., Wallace T.M., Hull R.L., Zraika S., et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48 (2005) 2330-2333
53. Minn A.H., Patterson N.B., Pack S., Hoffmann S.C., Gavrilova O., Vinson C., et al. Resistin is expressed in pancreatic islets. Biochem. Biophys. Res. Commun. 310 (2003) 641-645
54. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
55. Sethi J.K., and Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol. Med. 11 (2005) 344-347
56. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91 (2006) 295-299
57. Krzyzanowska K., Krugluger W., Mittermayer F., Rahman R., Haider D., Shnawa N., et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin. Sci. (Lond.) 110 (2006) 605-609
58. O'Carroll A.M., Selby T.L., Palkovits M., and Lolait S.J. Distribution of mrna encoding b78/apj, the rat homologue of the human apj receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim. Biophys. Acta 1492 (2000) 72-80
59. Lee D.K., Cheng R., Nguyen T., Fan T., Kariyawasam A.P., Liu Y., et al. Characterization of apelin, the ligand for the apj receptor. J. Neurochem. 74 (2000) 34-41
60. Reaux A., De Mota N., Skultetyova I., Lenkei Z., El Messari S., Gallatz K., et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. Neurochem. 77 (2001) 1085-1096
61. Chen M.M., Ashley E.A., Deng D.X., Tsalenko A., Deng A., Tabibiazar R., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 (2003) 1432-1439
62. Boucher J., Masri B., Daviaud D., Gesta S., Guigne C., Mazzucotelli A., et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146 (2005) 1764-1771
63. Sorhede Winzell M., Magnusson C., and Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul. Pept. 131 (2005) 12-17
64. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 (2005) 356-362
65. Cook K.S., Min H.Y., Johnson D., Chaplinsky R.J., Flier J.S., Hunt C.R., et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 237 (1987) 402-405
66. Millar C.A., Meerloo T., Martin S., Hickson G.R., Shimwell N.J., Wakelam M.J., et al. Adipsin and the glucose transporter glut4 traffic to the cell surface via independent pathways in adipocytes. Traffic 1 (2000) 141-151
67. Flier J.S., Cook K.S., Usher P., and Spiegelman B.M. Severely impaired adipsin expression in genetic and acquired obesity. Science 237 (1987) 405-408
68. Napolitano A., Lowell B.B., Damm D., Leibel R.L., Ravussin E., Jimerson D.C., et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int. J. Obes. Relat. Metab. Disord. 18 (1994) 213-218
69. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. (2006)
70. Monzillo L.U., Hamdy O., Horton E.S., Ledbury S., Mullooly C., Jarema C., et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes. Res. 11 (2003) 1048-1054
71. Von Eynatten M., Schneider J.G., Hadziselimovic S., Hamann A., Bierhaus A., Nawroth P.P., et al. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care 28 (2005) 754-755
72. Ballantyne G.H., Gumbs A., and Modlin I.M. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes. Surg. 15 (2005) 692-699
73. Hsieh C.J., Wang P.W., Liu R.T., Tung S.C., Chien W.Y., Chen J.F., et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res. Clin. Pract. 67 (2005) 78-83
74. Bajaj M., Suraamornkul S., Hardies L.J., Pratipanawatr T., and DeFronzo R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type ii diabetic patients. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 783-789
75. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L.J., and DeFronzo R.A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 4312-4319
76. Tamori Y., Sakaue H., and Kasuga M. Rbp4, an unexpected adipokine. Nat. Med. 12 (2006) 30-31 (discussion 31)